Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report
CONCLUSION: This case underlines the relative irrelevance of bone mineral density and clinical algorithms in predicting the risk of rebound-associated vertebral fractures after denosumab discontinuation and the strong recommendation to always switch to another antiresorptive therapy (such as zoledronic acid) immediately at the time of denosumab discontinuation.PMID:34238202 | DOI:10.2174/1871530321666210708142127
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Giangiacomo Osella Soraya Puglisi Anna Al ì Giuseppe Reimondo Massimo Terzolo Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Orthopaedics | Reclast | Xgeva | Zometa